Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2927-2933

  Wasif Saif, Muhammad ^a   Syrigos, Kostas ^b   Kaley, Kristin ^a   Isufi, Iris ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colon cancer; Gabapentin; Oxaliplatin; Peripheral neuropathy; Pregabalin

Indexed keywords

CAPECITABINE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; PREGABALIN;

ADULT; AGED; ARTICLE; ATAXIA; BLURRED VISION; CLINICAL ARTICLE; COLORECTAL CANCER; CONFUSION; CONSTIPATION; DIGESTIVE SYSTEM CANCER; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; MALE; MUSCLE TWITCH; NEUROLOGIC DISEASE; PANCREAS CANCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOMNOLENCE; STOMACH CANCER; THROMBOCYTOPENIA; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; FLUOROURACIL; GAMMA-AMINOBUTYRIC ACID; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS;

EID: 77955783269     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Culy CR, Clemett D and Wiseman LR: Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60: 895-924, 2000.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
3. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Gaggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL and Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil/leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000.
4. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
5. Grothey A: Oxaliplatin safety profile: neurotoxicity. Semin Oncol 4(suppl 15): 5-13, 2003.
6. Brienza S, Vignoud J, Itzhaki M and Krikorian A: Oxaliplatin (L-OHP): Global safety in 682 patients [abstract 513]. Proc Am Soc Clin Oncol 14: 209, 1995.
7. Gamelin E, Gamelin L, Bossi L and Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measurements. Semin Oncol 29(5 suppl 15): 21-33, 2002. (Pubitemid 35191038)
8. Lehky TJ, Leonard GD, Wilson RH, Grem JL and Floeter MK: Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29: 387-392, 2004.
9. Cavaletti G, Tredici G, Petruccioli MG, Dondè E, Tredici P, Marmioli P, Minoia C, Ronchi A, Bayssas M and Etienne GG: Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37: 2457-2463, 2001.
10. Graham J, Mushin M and Kirkpatrick P: Oxaliplatin. Nat Rev Drug Discov 3: 11-12, 2004.
11. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M and Gamelin E: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85: 2293-2297, 2001. (Pubitemid 32440704)
12. + channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25-32, 2000.
13. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK and Grem JL: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20: 1767-1774, 2002. (Pubitemid 34273265)
14. Tobe TJ, Braam GB, Meulenbelt J and van Dijk GW: Ethylene glycol poisoning mimicking Snow White. Lancet 359: 444-445, 2002. (Pubitemid 34158964)
15. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne L B, Gilles S, Boisdron-Celle M and Gamelin E: Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clin Cancer Res 13: 6359-6368, 2007. (Pubitemid 350075025)
16. + channels and its effect on closing rate. Proc Natl Acad Sci USA 96: 4154-4157, 1999.
17. Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A and Gamelin E: Prevention of oxaliplatin-related neurotoxicity by calcium magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10: 4055-4061, 2004. (Pubitemid 38812481)
18. Saif MW: Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 4: 576-582, 2004.
19. Wang WS, Lin JK, Lin TC, Chen WS, Jiang Jk, Wang HS, Chiou TJ, Liu JH, Yen CC and Chen PM: Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. The Oncologist 12: 312-319, 2007.
20. Gedlicka C, Scheithauer W, Schull B and Kornek GV: Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20: 3359-3360, 2002.
21. Afafitei RD, Schneider S, Iqbal S, Yang D, Groshen S and Lenz HJ: Effect of celecoxib on neurotoxicity in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin [abstract 3600]. ProcAm Soc Clin Oncol 22: 270s, 2004.
22. Maestri A, De Pasquale Ceratti A, Calandri C, Cundari A, Zanna C, Crino L and Cortesi E: Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy [abtract 2807]. Proc Am Soc Clin Oncol 21: 247b, 2002.
23. Marshall J, Zakari A, Hwang JJ, Papadopoulos V, Rosenberg A and Silver C: Ginkgo Biloba (GB) extract as a neuroprotective agent in oxaliplatin (Ox)-induced neuropathy [abstract 14S]. J Clin Oncol 22: 3670, 2004.
24. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W and Scheithauer W: Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 12: 421-422, 2001. (Pubitemid 32288702)
25. Lin PC, Lee MY, Wang WS, Yen CC, Chao TC, Hsiao LT, Yang MH, Chen PM, Lin KP and Chiou TJ: N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer 14: 484-487, 2006.
26. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U and Cattel L: Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs 20: 396-402, 2009.
27. Saif MW and Reardon J: Management of oxaliplatin-induced peripheral neuropathy. Therapeutics and Clinical Risk Management 1: 249-258, 2005.
28. Macdonald RL and Kelly KM: Antiepileptic drug mechanisms of action. Epilepsia e: S2-S12, 1995.
29. Rogawski MA and Taylor CP: Calcium channel α2-δ subunit, a new antiepileptic drug target. Epilepsy Res 69: 183-272, 2006.
30. Taylor C, Angelotti T and Fauman E: Pharmacology and mechanism of action of pregabalin: The calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 73: 137-150, 2007.
31. Mariani G, Garrone O, Granetto C, Numico G, LaCiura P, Grecchi G, DiCostanzo G and Merlano M: Oxaliplatin-induced neuropathy: Could gabapentin be the answer? [abstract 2397]. Proc Am Soc Clin Oncol 19: 609a, 2000.
32. Wong GY, Michalak JC, Sloan JA, Mailliard JA, Nikcevich DA, Warner DO, Loprinzi CL, Kutteh LA and Dakhil SR: A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study [abstract]. Proc Am Soc Clin One 23: 729s, 2005.
33. Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA and Clarke S: Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6: 146-151, 2006. (Pubitemid 44445750)
34. Tassone DM, Boyce E, Guyer J and Nuzum D: Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29: 26-48, 2007. (Pubitemid 46415802)
35. Gajraj NM: Pregabalin: Its Pharmacology and Use in Pain Management. Anesth Analg 105: 1805-15, 2007.
36. Bockbrader HN, Hunt T, Strand J, Posvar E and Sedman A: Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies [abstract P06.051]. Neurology 54(suppl 3):A421, 2000.
37. Busch JA, Strand JC, Posvar EL, Bockbrader HN and Radulovic LL: Pregabalin (CI-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of Pregabalin solution or capsule doses [abstract 2.108]. Epilepsia 39(Suppl 6): 58, 1998.
38. Frampton JE and Foster RH: Pregabalin in the treatment of postherpetic neuralgia. Drugs 65: 111-120, 2005.
39. Saif MW and Hashmi S: Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer. Cancer Chemotherapy and Pharmacology 61: 349-354, 2008.
40. Auger RG: Diseases associated with excess motor unit activity. Muscle Nerve 17: 1250-1263, 1994.
41. Caldron PH and Wilbourn AJ: Gold neurotoxicity and myokymia. J Rheumatol 15: 528-529, 1988.
42. Reeback J, Benton S, Swash M and Schartz, MS: Penicillamine-induced neuromyotonia. BMJ 1: 1464-1465, 1979.
43. + channels are implicated in neuromyotonia. Ann Neurol 41: 238-246, 1997. (Pubitemid 27082105)
44. Hart IK: Acquired neuromyotonia: A new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci 319: 209-216, 2000.
45. + channel inactivation. Neurology 56: 878-884, 2001. (Pubitemid 32290804)
46. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, Beretta GD, Ubiali E and Catalano G: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo controlled trial. J Clin Oncol 16: 3478-3483, 2002.
47. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S and Lersch C: Prevention of oxaliplatin neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr 127: 78-82, 2003.
48. Freynhagen R, Strojek K, Griesing T, Whalen E and Balkenohl M: Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115: 254-263, 2005. (Pubitemid 40725282)
49. Guay DR: Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother 3: 274-287, 2005.
50. Lyrica[package insert]. New York, NY: Pfizer Inc.; 2005.
51. Neurontin [package insert]. New York, NY: Pfizer, Inc.; 2004.